Innate Pharma Reports First Half 2021 Financial Results and Business Update
Monalizumab and ANKET™ Data will be Presented at ESMO 2021 Virtual Congress
Innate Pharma reports Full Year 2020 financial results and business update
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Innate Pharma reports first half 2020 financial results and business update
Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
Innate Pharma third quarter 2019 report
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
Monalizumab to advance to Phase III in head and neck cancer
